A recombinant baculovirus vector vaccine (BacMCP) against the infectious spleen and kidney necrosis virus (ISKNV)

© 2022 John Wiley & Sons Ltd.

Détails bibliographiques
Publié dans:Journal of fish diseases. - 1998. - 46(2023), 2 vom: 24. Feb., Seite 165-176
Auteur principal: Zhu, Min (Auteur)
Autres auteurs: Shen, Zeen, Gu, Yuchao, Tong, Xinyu, Zhang, Yaxin, Pan, Jun, Feng, Yongjie, Hu, Xiaolong, Wang, Yujun, Cao, Guangli, Xue, Renyu, Gong, Chengliang
Format: Article en ligne
Langue:English
Publié: 2023
Accès à la collection:Journal of fish diseases
Sujets:Journal Article baculovirus vector vaccine infectious spleen and kidney necrosis virus (ISKNV) largemouth bass Viral Vaccines Vaccines, Synthetic Capsid Proteins
Description
Résumé:© 2022 John Wiley & Sons Ltd.
The infectious spleen and kidney necrosis virus (ISKNV) is a highly lethal virus, which has brought significant losses to aquaculture. Therefore, a new vaccine against ISKNV with high efficiency, safety and convenience must be developed. While baculoviruses are more commonly used as protein expression systems for vaccine antigen production, this paper used baculovirus technology to develop a live-vector vaccine, BacMCP, which contains the coding sequence of the major capsid protein (MCP) (GenBank accession no. AF371960) of ISKNV and is driven by a CMV promoter. Real-time PCR and immunofluorescence showed that the MCP gene was successfully delivered to and expressed in fish cells and tissues inoculated with BacMCP. Immune-related gene (IgM, TGF-β, IL-1, IL-8, TNF-α) expression was induced in BacMCP-treated groups of largemouth bass compared with control groups. Specific antibodies could be detected in the serum of BacMCP injection-vaccinated largemouth bass by ELISA. After injection or immersion vaccination with BacMCP for 21 days, largemouth bass were infected with ISKNV. The immune effect of the injected immunization on fish in different sizes was evaluated. The vaccine efficacy of injection-vaccinated bass was 100% in small bass and 85.7% in large bass. The vaccine efficacy of immersion-vaccinated small bass was 77.3%. This study suggested that BacMCP can be used as a vector-based vaccine candidate to prevent the diseases caused by ISKNV infection
Description:Date Completed 12.01.2023
Date Revised 12.01.2023
published: Print-Electronic
Citation Status MEDLINE
ISSN:1365-2761
DOI:10.1111/jfd.13731